PharmiWeb.com - Global Pharma News & Resources

Clinical research - Press Releases

Date Title Company
17-Sep-2024 A global pharma showcase: MM Packaging readies for CPHI 2024 MM Packaging
17-Sep-2024 OrganaBio Expands Cell and Gene Therapy Donor Base to Include Patients with Lupus, Other Autoimmune Diseases OrganaBio
17-Sep-2024 ScaleReady announces a G-Rex® Grant has been awarded to Verismo Therapeutics Verismo Therapeutics
17-Sep-2024 AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease AC Immune SA
17-Sep-2024 ImmunOs Therapeutics AG Raises $11 Million and Further Strengthens Investor Base ImmunOs Therapeutics
16-Sep-2024 Refeyn establishes new mass photometry Scientific Advisory Board to maximize potential of transformative technology Refeyn Ltd
16-Sep-2024 AAVantgarde announces first patient dosed in First-In-Human Phase 1/2 LUCE-1 study, evaluating AAVB-081 (Dual-AAV) in retinitis pigmentosa related to Usher Syndrome type 1B AAVantgarde Bio
16-Sep-2024 Certa Therapeutics Announces International Non-Proprietary Name for its First-in-class GPR68 Inhibitor Asengeprast (FT011) Certa Therapeutics
16-Sep-2024 Inauguration of the New Richter BioLogics cGMP Facility for the Manufacture of Biopharmaceuticals for the Global Market Richter BioLogics GmbH & Co KG
16-Sep-2024 China patent notification boosts PolTREG’s development of Treg cell therapy in multiple sclerosis PolTREG
16-Sep-2024 Transgene and BioInvent’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatments Transgene
13-Sep-2024 Optalitix secures further $3m led by Calculus Capital to accelerate ambitious growth strategy Optalitix
13-Sep-2024 Cytovation to present full safety and efficacy data from the CICILIA Phase I/IIa trial evaluating CY-101 in solid tumors at ESMO 2024 Cytovation ASA
13-Sep-2024 Clinical Research Training: Your Path to a Successful Career Fusion technology solutions
12-Sep-2024 Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second Pivotal Phase 3 Trial Gilead’s
12-Sep-2024 Biocomposites to distribute its NanoBone® product range in the UK Biocomposites
12-Sep-2024 Epitopea Awarded Grant from Innovate UK’s Cancer Therapeutics Programme Epitopea
12-Sep-2024 KADANS SCIENCE PARTNER WELCOMES NEW TENANT MYRICX BIO TO LONDON INNOVATION CENTRE AT CANARY WHARF Kadans Science Partner
12-Sep-2024 Arctoris acquires Eli Lilly ‘Life Science Studio’ laboratory Arctoris
12-Sep-2024 Vapourtec invests in future with Bristol CDT partnership Vapourtec